Company · Private

Altos Labs

Research-first company pursuing partial epigenetic reprogramming to restore cell health and function. Heavily funded, deliberately pre-clinical, and publishing in the open literature rather than racing to a single asset.

Listing

Private

Ticker

—

Headquarters

San Francisco, US / Cambridge, UK

Founded

2021

Technology

Cellular reprogramming

Longevity thesis

If cellular age can be partially reset without loss of cell identity, a single platform could address several age-related diseases instead of one indication at a time.

Programmes

Partial reprogramming platformDiscovery
Rejuvenation of aged tissue
Hepatic regenerationPreclinical
Liver injury repair
Neuronal resilienceDiscovery
Neurodegeneration

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.